Latest & greatest articles for alendronate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alendronate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alendronate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alendronate

61. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. (PubMed)

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment.We carried out two 48-week, randomized, placebo-controlled studies of two doses of alendronate in 477 men and women, 17 to 83 years of age, who were receiving glucocorticoid therapy. The primary end point (...) was the difference in the mean percent change in lumbar-spine bone density from base line to week 48 between the groups. Secondary outcomes included changes in bone density of the hip, biochemical markers of bone turnover, and the incidence of new vertebral fractures.The mean (+/-SE) bone density of the lumbar spine increased by 2.1+/-0.3 percent and 2.9+/-0.3 percent, respectively, in the groups that received 5 and 10 mg of alendronate per day (P<0.001) and decreased by 0.4+/-0.3 percent in the placebo group

1998 NEJM

62. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. (PubMed)

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear. Whether other antiresorptive therapies can prevent osteoporosis in these women is also not clear.We studied the effect of 2.5 mg or 5 mg of alendronate per day or placebo (...) at all measured sites, whereas the women treated with 5 mg of alendronate daily had a mean (+/-SE) increase in bone mineral density of 3.5+/-0.2 percent at the lumbar spine, 1.9+/-0.1 percent at the hip, and 0.7+/-0.1 percent for the total body (all P<0.001). Women treated with 2.5 mg of alendronate daily had smaller increases in bone mineral density. Alendronate did not increase bone mineral density of the forearm, but it slowed the loss. The responses to estrogen-progestin were 1 to 2 percentage

1998 NEJM

63. Bisphosphonates (alendronate and etidronate) in the management of osteoporosis

Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Best L, Milne R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Best L, Milne R. Bisphosphonates (...) (alendronate and etidronate) in the management of osteoporosis. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1998 Authors' objectives The authors examine whether alendronate and etidronate should be used in the treatment of diagnosed osteoporosis. Authors' conclusions The authors find that the choice of target population is critical to the cost-utility of bisphosphonate treatment. If treatment is targeted towards individuals at high risk of fracture then both alendronate

1998 Health Technology Assessment (HTA) Database.

64. Meta-analysis of prevention of nonvertebral fractures by alendronate. (PubMed)

Meta-analysis of prevention of nonvertebral fractures by alendronate. 9272885 1997 09 10 2016 10 17 0098-7484 278 8 1997 Aug 27 JAMA JAMA Meta-analysis of prevention of nonvertebral fractures by alendronate. 631; author reply 631-2 Ross S D SD eng Comment Letter United States JAMA 7501160 0098-7484 X1J18R4W8P Alendronate AIM IM JAMA. 1997 Apr 9;277(14):1159-64 9087473 Alendronate therapeutic use Female Fractures, Bone prevention & control Humans Meta-Analysis as Topic Osteoporosis

1997 JAMA

65. Meta-analysis of prevention of nonvertebral fractures by alendronate. (PubMed)

Meta-analysis of prevention of nonvertebral fractures by alendronate. 9272886 1997 09 10 2016 10 17 0098-7484 278 8 1997 Aug 27 JAMA JAMA Meta-analysis of prevention of nonvertebral fractures by alendronate. 631; author reply 631-2 Prostko M M eng Comment Letter United States JAMA 7501160 0098-7484 X1J18R4W8P Alendronate AIM IM JAMA. 1997 Apr 9;277(14):1159-64 9087473 Alendronate economics therapeutic use Cost-Benefit Analysis Female Fractures, Bone prevention & control Humans Osteoporosis

1997 JAMA

66. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. (PubMed)

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. To evaluate the effect of treatment with alendronate sodium, a potent aminobisphosphonate, on the incidence of nonvertebral fractures in postmenopausal women with osteoporosis.Published data and data on file at Merck Research Laboratories.All completed prospective, randomized, placebo-controlled alendronate trials of at least 2 years' duration (5 studies).All subjects were (...) women with osteoporosis between the ages of 42 and 85 years, postmenopausal at least 4 years, with lumbar spine bone mineral density (measured using dual-energy x-ray absorptiometry) at least 2.0 SD below the mean for young adult women. All women randomized to treatment with placebo or alendronate at a dose higher than 1 mg per day for at least 2 years were included.In the placebo group (n=590), 60 women reported nonvertebral fractures during 1347 patient-years at risk (overall rate, 4.45 women

1997 JAMA

67. [Use of alendronate in osteoporosis: is it cost-effective?]

[Use of alendronate in osteoporosis: is it cost-effective?] Bruk av alendronat ved osteoporose: er det kostnadseffektivt? [Use of alendronate in osteoporosis: is it cost-effective?] Bruk av alendronat ved osteoporose: er det kostnadseffektivt? [Use of alendronate in osteoporosis: is it cost-effective?] Kristiansen I S, Falch J A, Andersen L, Aursnes I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of alendronate in the treatment of osteoporosis. Type of intervention Treatment, primary prevention and secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Women with a bone mass density (BMD) less than 2.5 standard deviations below maximum BMD (the WHO

1997 NHS Economic Evaluation Database.

68. Prevention of nonvertebral fractures by alendronate: a meta-analysis

Prevention of nonvertebral fractures by alendronate: a meta-analysis Prevention of nonvertebral fractures by alendronate: a meta-analysis Prevention of nonvertebral fractures by alendronate: a meta-analysis Karpf D B, Shapiro D R, Seeman E, Ensrud K E, Johnston C C, Adami S, Harris S T, Santora A C, Hirsch L J, Oppenheimer L, Thompson D Authors' objectives To evaluate the effect of treatment with alendronate sodium, an aminobisphosphonate, on the incidence of nonvertebral fractures in post (...) -menopausal women with osteoporosis. Searching Studies were sought from published data and data on file at Merck Research Laboratories. No search details were provided. Study selection Study designs of evaluations included in the review The studies evaluated were all randomised, prospective double-blind placebo controlled trials of at least two years duration that evaluated the efficacy of treatment with daily oral alendronate. Specific interventions included in the review Daily treatment with various

1997 DARE.

69. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. (PubMed)

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Previous studies have shown that alendronate can increase bone mineral density (BMD) and prevent radiographically defined (morphometric) vertebral fractures. The Fracture Intervention Trial aimed to investigate the effect of alendronate on the risk of morphometric as well as clinically evident fractures in postmenopausal women with low bone (...) mass.Women aged 55-81 with low femoral-neck BMD were enrolled in two study groups based on presence or absence of an existing vertebral fracture. Results for women with at least one vertebral fracture at baseline are reported here. 2027 women were randomly assigned placebo (1005) or alendronate (1022) and followed up for 36 months. The dose of alendronate (initially 5 mg daily) was increased (to 10 mg daily) at 24 months, with maintenance of the double blind. Lateral spine radiography was done

1996 Lancet

70. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. (Full text)

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. Postmenopausal osteoporosis is a serious health problem, and additional treatments are needed.We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo (...) or alendronate (5 or 10 mg daily for three years, or 20 mg for two years followed by 5 mg for one year); all the women received 500 mg of calcium daily. Bone mineral density was measured by dual-energy x-ray absorptiometry. The occurrence of new vertebral fractures and the progression of vertebral deformities were determined by an analysis of digitized radiographs, and loss of height was determined by sequential height measurements.The women receiving alendronate had significant, progressive increases

1995 NEJM PubMed